Skip to main content
OpenTrials
Completed

NCT Number: NCT01931540

Developmental ORIgins of Healthy and Unhealthy AgeiNg: the Role of Maternal Obesity

The prevalence of obesity in the developed world has increased markedly over the last 20 years. Considering the prevalence of obese and overweight adult subjects, and the fact that pregnancy itself induces a state of insulin resistance and inflammation, maternal obesity may be the most common health risk for the developing fetus. It is well established that what we eat has a major impact on our health. However, there is growing evidence to suggest that diet during pregnancy and lactation may be particularly important as not only does it influence the health of the mother, it may have a permanent effect on the health of her children and even her grandchildren. The concept that environmental factors, such as nutrition during early development, influence both our health span and lifespan has been termed the developmental origins of health and disease hypothesis.

The objective of the study are:

* to compare subjects with frailty (condition developed with ageing) with controls and characterize the unhealthy aged condition with the measurements described below * to examine if signs of frailty can be reversed by lifestyle induced modifications (exercise training programme) of its primary components (IR, sarcopenia, psychological profile) in offspring of overweight/obese (OOM) vs lean mothers (OLM).

The study consists of 37 frail old subjects, age ≥ 65 sub-grouped in 17 OOM, and 20 OLM and 11 non frail controls. These subjects will be studied with positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI) and spectroscopy (MRS) and ultra sounds (US). In addition functional MRI (fMRI) will be performed. Adipose tissue biopsies will be taken.

Subjects will undergo characterization of biohumoral markers, a 75 g oral glucose tolerance test, imaging biomarkers (PET/CT, US, fMRI-MRS), genetic biomarkers (DNA and telomere damage) and inflammatory biomarkers (macrophage infiltration) before and after the 4-month lifestyle intervention period (physical exercise). By PET/CT it will be measured tissue-specific IR in skeletal muscle, adipose tissue, liver, myocardium and targeted brain regions. MRS will be used to measure organ steatosis in the skeletal muscle and liver, MRI will be used to measure fat masses in abdominal areas, and fMRI will be performed to assess activation in brain regions regulating cognition and appetite/energy control. US will be used to assess cardiovascular markers (IMT, strain and function).

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Helsinki, Department of General Practice and Primary Health Care, Helsinki, Finland

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must be already participating the Helsinki Birth Cohort Study

Frailty Groups Inclusion Criteria:

  • (Frailty) with lowest half of adult grip strength (measured 2001-2004)
  • Group OM: (Offspring of Obese mothers) Highest quartile of maternal BMI
  • Group LM: (Offspring of Normal weight/Lean mothers) Lowest two quartiles of maternal BMI

Control group Inclusion Criteria:

  • (no Frailty) with highest half of adult grip strength (measured 2001-2004)
  • Offspring of normal weight mothers

Exclusion criteria

  • Subjects whose mothers were pre-eclamptic during pregnancy
  • Oral corticosteroid or Warfarin therapy
  • Recent myocardial infarction
  • Severe chronic disorder that can prevent to participate the intervention
  • Chronic atrial fibrillation and pacemaker
  • Cancer less than 5 years ago
  • Current smoking
  • Diabetes requiring insulin treatment or fasting glucose more than 7 mmol/l
  • Weight more than 170 kg and Waist circumference > 150 cm
  • Inner ear implants
  • Metal objects in body including metallic prostheses, artificial valve prostheses, surgical clips, braces, foreign fragments or tattoo

Treatment and study plan

Exercise Training

Behavioral

Three times a week, for four months.

Primary outcomes

  1. Baseline group comparison and Change from Baseline in Insulin-stimulated whole body and organ-specific glucose uptake at 4 months

    Time frame: At day 1 and after 4 months of intervention (for the 15 controls only at baseline)

    Assessed via 18F-Fluorodeoxyglucose (FDG)-PET/CT+Clamp technique

  2. Baseline group comparison and Change from Baseline in Epigenetic characterization of DNA samples (Telomere length, H2A.X phosphorilation, mtDNA deletion, p66) at 4 months

    Time frame: At day 1 and after 4 months of intervention (for the 15 controls only at baseline)

    Telomere length, H2A.X phosphorilation, mtDNA deletion are measurements performed in Pisa, National Research Council p66 presence is measured in Rome, Istituto Superiore di Sanita'

Secondary outcomes

  1. Baseline group comparison and Change from Baseline in Fat masses and content via MRI and MRS at 4 months

    Time frame: At day 1 and after 4 months of intervention (for the 15 controls only at baseline)

    Adipose tissue fat masses in different depots (subcutaneous, visceral, pericardial) Liver, skeletal muscle, vertebral fat content

  2. Baseline group comparison and Change from Baseline in MRI brain anatomy and fMRI characterization of activation response to food stimuli of different brain regions at 4 months

    Time frame: At day 1 and after 4 months of intervention

    MRI anatomy: White matter volume, Cortex thickness, Nerve tracks found with Diffusor Tension Imaging fMRI will be used to identify different brain regions activated by food stimuli while subjects perform three different task: watch the food, think of eating the food, control the urge to eat the food.

Sponsors and collaborators

Lead sponsor

Turku University Hospital

Other Gov

Collaborators

  • Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
  • Istituto Superiore di Sanità
  • University of Helsinki
  • University of Turku

Registry information

Acronym: DORIAN

Important dates

Study start
2012
Primary completion
2014
Study completion
2015
First posted
Aug 29, 2013
Registry last updated
Mar 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.